Biogen Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher A. Viehbacher
- Full Time Employees
- 7,605
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 225 Binney Street Cambridge MA United States of America 02142
- IPO Date
- Sep 17, 1991
- CIK
- 0000875045
- Website
- biogen.com
- Similar Companies
- Business
- Biogen Inc. (BIIB) discovers, develops, manufactures and commercializes therapies for neurological and neurodegenerative diseases, hemophilia, multiple sclerosis (MS), spinal muscular atrophy (SMA), lupus and rare diseases worldwide; core products include Tecfidera and Vumerity (dimethyl and diroximel fumarate) for MS, Avonex (interferon beta-1a), Plegridy (peginterferon beta-1a) and Tysabri (natalizumab) for relapsing MS, Spinraza for SMA, Leqembi for Alzheimer's disease, Skyclarys for Friedreich's ataxia and anti-CD20 therapies such as Rituxan and Gazyva for certain B-cell malignancies and autoimmune conditions. The company, founded in 1978 and headquartered in Cambridge, Massachusetts, operates in the United States, Europe, Asia and other international markets. Recent developments include the completion of its acquisition of Alcyone Therapeutics in November 2025 to bolster rare disease capabilities, a November 2025 collaboration with Dayra Therapeutics featuring a $50 million upfront payment for oral macrocyclic peptides targeting immunology, a February 2025 R&D funding agreement with Royalty Pharma worth up to $250 million for Phase 3 litifilimab in lupus, expansion of Leqembi with U.S. approval of the IQLIK subcutaneous formulation, an agreement to acquire Sage Therapeutics and groundbreaking in September 2025 for a new 580,000-square-foot headquarters at 75 Broadway set for completion in 2028 coinciding with the company's 50th anniversary.
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
Amgen or Biogen: Which Biotech Stock Appears Better Poised?
New Strong Sell Stocks for June 30th
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?
Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB
Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
Biogen to acquire RayThera for $1 billion
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
The Healthcare M&A Wave
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB